Pampers taps Jennifer Hudson for exclusive lullaby
NEW YORK — Pampers has teamed up with a Grammy Award-winning recording artist to celebrate the love parents feel for their babies.
Pampers said Jennifer Hudson, who is a mom herself, teamed up with the diaper brand to record an original rendition of the bedtime classic "Lullaby and Goodnight," which is exclusively available for free download on Pampers’ Facebook page. Pampers said the partnership with Hudson underscores Pampers’ commitment to the nurturing of babies everywhere through music and noted that the brand is planning to roll out music-inspired online engagement campaigns for its community. Pampers also will celebrate its partnership with Hudson by making a $100,000 donation to Jennifer Hudson’s charity, the Julian D. King Gift Foundation, to benefit moms, toddlers and babies.
In addition to being able to download Hudson’s lullaby recording, parents also will be able to interact with Pampers Lullabies application on Facebook, which will allow parents to create their own lullabies for their babies tapping original Pampers musical tracks, post them to the Pampers gallery for others to view and share them with family and friends. The app will launch next month.
“Music offers a powerful and emotional way to enhance the natural loving connection between parent and child,” Pampers general manager Fama Francisco said. "We are thrilled to pay tribute to the beautiful role of songs — and in particular to the endearing role of the evening-time lullaby — by teaming up with Grammy winner and mom Jennifer Hudson to offer parents a contemporary, fresh take on a bedtime favorite. The joyful spirit of music offers moms just one more way to express love for their little ones and ease their transition into peaceful sleep.”
APhA introduces acetaminophen continuing-education program for pharmacists
WASHINGTON — A new continuing-education program offered by a national pharmacist professional organization aims to prepare pharmacists to communicate with patients about the safe and effective use of the painkiller acetaminophen.
The American Pharmacists Association said its new CE program would allow pharmacists to outline the Food and Drug Administration’s recent advisory panel meetings on the drug, communicate with patients about its appropriate use, and engage consumers in dialogue and such activities as reading labels of products containing acetaminophen.
The drug, which is the active ingredient of Tylenol and is found in more than 600 prescription and over-the-counter medications, carries little risk for patients using it as directed, but also can cause serious liver injury. Many cases of overdose result from patients taking too much of the drug or taking multiple products containing it. In response, the FDA asked drug makers in January 2011 to limit the amount of acetaminophen in prescription combination pain relievers that include it and such drugs as oxycodone and codeine to no more than 325 mg per tablet or capsule to reduce overdoses and severe liver injury.
Mylan joins patent challenge on Pfizer antidepressant drug
PITTSBURGH — Mylan is challenging the patent protection on a Pfizer drug for treating depression, following an announcement of a similar challenge by Watson made earlier this week.
Mylan said it had filed for Food and Drug Administration approval of a generic version of Pristiq (desvenlafaxine succinate) extended-release tablets in the 50-mg and 100-mg strengths.
The application contained a paragraph IV certification, a legal assertion that the drug’s patent protection is invalid, unenforceable or won’t be infringed, prompting a patent-infringement lawsuit by Pfizer and others in the U.S. District Court for the District of Delaware.
Watson announced Tuesday that it also had challenged the drug’s patent protection and was sued, and Mylan said it expected to share a 180-day period of market exclusivity in which to compete directly with Pfizer’s product following FDA approval.
Pristiq had sales of $559.4 million during the 12-month period ended in March, according to IMS Health.